ArticleCancers2021
Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Change in skeletal muscle mass during systemic cancer treatment: a systematic review and meta-analysis.Acta oncologica (Stockholm, Sweden) · 2026Pooled it
- Associations of body composition with neoadjuvant chemotherapy response, toxicity, and prognosis in breast cancer: a scoping review.Cancer chemotherapy and pharmacology · 2026Article
- Nomograms Integrating Body Composition Metrics Predict Total Pathologic Complete Response after Neoadjuvant Systemic Therapy for Breast Cancer.Cancer research and treatment · 2026Article
- Article
- Fusion model integrating multi-sequence MRI radiomics and habitat imaging for predicting pathological complete response in breast cancer treated with neoadjuvant therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Mechanisms, assessment, and exercise interventions for skeletal muscle dysfunction post-chemotherapy in breast cancer: from inflammation factors to clinical practice.Frontiers in oncology · 2025Review
- Sarcopenia's Role in Neoadjuvant Chemotherapy Outcomes for Locally Advanced Breast Cancer: A Retrospective Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Myogenic microRNAs as Therapeutic Targets for Skeletal Muscle Mass Wasting in Breast Cancer Models.International journal of molecular sciences · 2024Review
- Article
- Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma.Annals of gastroenterological surgery · 2023Article
- Significant impact of cachexia index on the outcomes after hepatic resection for colorectal liver metastases.Annals of gastroenterological surgery · 2022Article
- Exercise-Induced Circulating microRNAs: Potential Key Factors in the Control of Breast Cancer.Frontiers in physiology · 2022Article
- Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles.Frontiers in pharmacology · 2022Review
- Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
There are no means to predict patient response to neoadjuvant chemotherapy (NAC); the impact of skeletal muscle loss on the response to NAC remains undefined. We investigated the association between response to chemotherapy and skeletal muscle loss in breast cancer patients. Patients diagnosed with invasive breast cancer who were treated with NAC, surgery, and radiotherapy were analyzed. We quantified skeletal muscle loss using pre-NAC and post-NAC computed tomography scans. The response to treatment was determined using the Response Evaluation Criteria in Solid Tumors. We included 246 patients in this study (median follow-up, 28.85 months). The median age was 48 years old (interquartile range 42-54) and 115 patients were less than 48 years old (46.7%). Patients showing a complete or partial response were categorized into the responder group (208 patients); the rest were categorized into the non-responder group (38 patients). The skeletal muscle mass cut-off value was determined using a receiver operating characteristic curve; it showed areas under the curve of 0.732 and 0.885 for the pre-NAC and post-NAC skeletal muscle index (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.